About Clinigen Group

Clinigen Group plc is a rapidly-growing global specialty pharmaceutical and services company with a unique combination of businesses focused on delivering the right medicine to the right patient at the right time to improve the quality of people’s lives around the world. The Group’s unique business model is focused in three areas of global medicine supply: clinical trial, unlicensed and licensed medicines.

Headquartered in Staffordshire, Clinigen has 4 offices in the UK and 3 distribution hubs, serving a global customer base of over 250 pharmaceutical and biotech companies and over 6,000 healthcare professionals. With decades of expertise the UK team supports the provision of access to medicines throughout the product lifecycle. On in house expertise covers for Quality Assurance, Medical Information, Regulatory, Logistics and Medicine Access, ensuring the highest quality medicines are sourced, manufactured and supplied, and unmet patient need is met. With a Medicines Access team who speak over 25 languages, we provide healthcare professionals with seamless service in their local language, always working within the appropriate legal, regulatory and ethical frameworks, getting the right medicine to patients in the shortest possible time. That is why we are trusted to manage innovative products by our pharmaceutical and biotech partners around the world.

Clinigen’s UK team of 650 staff work closely with our global sites in the US, Australia, China, Japan, South Africa, Greece and Singapore (over 560 staff in total across 13 locations), to provide medicines for use in clinical trials and unlicensed and commercial supply whenever and where the need arises.

History

Clinigen’s roots began in the UK. Formed in 2010 through the merger of three successful companies: Keats Healthcare, which became Clinigen (Clinical Trial Services) CTS; Clinigen Healthcare which became Clinigen (Global Access Programs) GAP; and Clinigen, which became Clinigen (Specialty Pharmaceuticals) SP, Clinigen’s unique business model was built to provide access to both licensed and unlicensed medicines to patients all over the world. Clinigen achieved exponential growth, acquiring four products by 2014 and, in owning its own medicines, gaining unique insights into the challenges pharmaceutical and biotech companies face and unparalleled experience in ensuring the highest quality control and compliance standards. In 2015, Clinigen acquired Idis Limited and the Link Healthcare Group. Not only did these acquisitions strengthen Clinigen by bringing almost 5 decades of experience; Clinigen also became the global leader in providing ethical, compliant access to unlicensed medicines, expanding its capability to provide access to medicines for patients in the AAA (Africa, Australasia and Asia) region.

In November 2017 Clinigen acquired Quantum Pharma Plc. The addition of Quantum’s manufacturing and product development capabilities accelerates the Group’s unlicensed to licensed global strategy.